A cancer drug sold under the name Sprycel, priorly known as BMS-354825 is also called Dasatinib. Bristol-Myers Squibb is the producers of this drug. The drug is given approval for the first-line usage for treatment of patients affected by chronic myelogenous leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). It is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the “Philadelphia chromosome”) and Src family tyrosine kinase inhibitor.  It was announced by the U.S. Food and Drug Administration (FDA)  that this particular drug, Dasatinib might lead to increased risks of a not very common but serious condition in which the patient could experience abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Swelling of legs, ankles, fatigue and shortness of breath are associated with PAH. In cases that were reported, the patients developed PAH after being administered Dasatinib, including after more than a year of treatment.